Similarly, numerous reports based on in vitro studies and glioblastoma tissues have documented the significant role of EGFR amplification and mutations in glioblastoma progression, although it is important to note that in 30–40% of glioblastomas, EGFR amplification does not occur [29,52], and EGFRvIII mutations are observed in only 20% of high-grade gliomas [52,53]. This evidence concerns the gene EGFR and central nervous system cancer.